Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biomx Inc PHGE

Healthcare Biotechnology
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer... see more

Recent & Breaking News (NYSEAM:PHGE)

BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors

GlobeNewswire May 12, 2023

BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023

GlobeNewswire May 8, 2023

BiomX Announces Second Closing of $7.5 Million Private Placement

GlobeNewswire May 5, 2023

BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire March 29, 2023

BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023

GlobeNewswire March 27, 2023

BiomX Announces $7.5 Million Private Placement

GlobeNewswire February 22, 2023

BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

GlobeNewswire February 22, 2023

BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

GlobeNewswire November 29, 2022

BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 9, 2022

BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022

GlobeNewswire November 2, 2022

BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference

Business Wire September 11, 2022

BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update

Business Wire August 10, 2022

BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022

Business Wire August 7, 2022

BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease

Business Wire August 4, 2022

BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange

Business Wire July 6, 2022

Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers

Business Wire June 28, 2022

BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

Business Wire June 27, 2022

BiomX Announces Corporate Restructuring

Business Wire May 24, 2022

BiomX Announces Publication in the Journal, Bioinformatics

Business Wire May 20, 2022

BiomX Reports First Quarter 2022 Financial Results and Provides Business Update

Business Wire May 11, 2022